Literature DB >> 12766252

The endogenous cannabinoid anandamide inhibits alpha7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes.

Murat Oz1, Arippa Ravindran, Oscar Diaz-Ruiz, Li Zhang, Marisela Morales.   

Abstract

The effect of the endogenous cannabinoid ligand anandamide on the function of the cloned alpha7 subunit of the nicotinic acetylcholine (ACh) receptor expressed in Xenopus oocytes was investigated by using the two-electrode voltage-clamp technique. Anandamide reversibly inhibited nicotine (10 microM) induced-currents in a concentration-dependent manner (10 nM to 30 microM), with an IC50 value of 229.7 +/- 20.4 nM. The effect of anandamide was neither dependent on the membrane potential nor meditated by endogenous Ca2+ dependent Cl- channels since it was unaffected by intracellularly injected BAPTA and perfusion with Ca2+-free bathing solution containing 2 mM Ba2+. Anandamide decreased the maximal nicotine-induced responses without significantly affecting its potency, indicating that it acts as a noncompetitive antagonist on nicotinic acetylcholine (nACh) alpha7 receptors. This effect was not mediated by CB1 or CB2 receptors, as neither the selective CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR 141716A) nor CB2 receptor antagonist N-((1S)-endo-1,3,3-trimethyl-bicyclo-heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR 144528) reduced the inhibition by anandamide. In addition, inhibition of nicotinic responses by anandamide was not sensitive to either pertussis toxin treatment or to the membrane permeable cAMP analog 8-Br-cAMP (0.2 mM). Inhibitors of enzymes involved in anandamide metabolism including phenylmethylsulfonyl fluoride, superoxide dismutase, and indomethacin, or the anandamide transport inhibitor AM404 did not prevent anandamide inhibition of nicotinic responses, suggesting that anandamide itself acted on nicotinic receptors. In conclusion, these results demonstrate that the endogenous cannabinoid anandamide inhibits the function of nACh alpha7 receptors expressed in Xenopus oocytes in a cannabinoid receptor-independent and noncompetitive manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766252     DOI: 10.1124/jpet.103.049981

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 4.  Endocannabinoids in the dentate gyrus.

Authors:  Charles J Frazier
Journal:  Prog Brain Res       Date:  2007       Impact factor: 2.453

5.  Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy.

Authors:  Eleonora Palma; Jorge Mauricio Reyes-Ruiz; Diego Lopergolo; Cristina Roseti; Cristina Bertollini; Gabriele Ruffolo; Pierangelo Cifelli; Emanuela Onesti; Cristina Limatola; Ricardo Miledi; Maurizio Inghilleri
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

Review 6.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

Review 7.  New mechanisms and perspectives in nicotine withdrawal.

Authors:  K J Jackson; P P Muldoon; M De Biasi; M I Damaj
Journal:  Neuropharmacology       Date:  2014-11-26       Impact factor: 5.250

8.  The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.

Authors:  Murat Oz; Vanaja Jaligam; Sehamuddin Galadari; George Petroianu; Yaroslav M Shuba; Toni S Shippenberg
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

9.  Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.

Authors:  Miriam Melis; Giuliano Pillolla; Antonio Luchicchi; Anna Lisa Muntoni; Sevil Yasar; Steven R Goldberg; Marco Pistis
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

10.  Methanandamide blocks amphetamine-induced behavioral sensitization in rats.

Authors:  Bruce A Rasmussen; Ellen M Unterwald; Jae K Kim; Scott M Rawls
Journal:  Eur J Pharmacol       Date:  2009-10-30       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.